BiotechTube

0.09% cyclosporine A ophthalmic solution

Pre-clinicalCompleted
1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dry Eye Disease

Conditions

Dry Eye Disease

Trial Timeline

May 19, 2023 → Feb 20, 2024

NCT ID
NCT05957211

About 0.09% cyclosporine A ophthalmic solution

0.09% cyclosporine A ophthalmic solution is a pre-clinical stage product being developed by Sun Pharmaceutical for Dry Eye Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05957211. Target conditions include Dry Eye Disease.

What happened to similar drugs?

20 of 20 similar drugs in Dry Eye Disease were approved

Approved (20) Terminated (1) Active (0)
✅EvolocumabHeartFlowApproved
✅Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)CelltrionApproved
✅Infliximab + Infliximab + InfliximabCelltrionApproved
✅YMC026 + PlaceboYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05957211Pre-clinicalCompleted

Competing Products

20 competing products in Dry Eye Disease

See all competitors
ProductCompanyStageHype Score
COVID-19 VaccineModernaPreclinical
0
exidavnemab + Placebo ComparatorBioArctic ABPhase 2
36
mRNA-1975ModernaPhase 2
0
mRNA-3745ModernaPhase 2
0
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
UB-312 + PlaceboVaxxinityPhase 1
19
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
21
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
Abiprubart + PlaceboKiniksa PharmaceuticalsPhase 2
21
atomoxetine + Matching PlaceboEli LillyPhase 2
35
Rosuvastatin 40mg + PlaceboHeartFlowPre-clinical
27
EvolocumabHeartFlowApproved
29
High intensity lipid loweringHeartFlowPre-clinical
20
Apixaban 5 MG + Apixaban 2.5 MG + WarfarinArtivionPhase 3
26
LanifibranorInventivaPhase 2
29
LY450139 + PlaceboEli LillyPhase 3
40
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
VTX958 + VTX958 + VTX958 PlaceboVentyx BiosciencesPhase 2
21
Solanezumab + PlaceboEli LillyPhase 3
32